Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans

October 17, 2024

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.

Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges

October 16, 2024

Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review

October 15, 2024

Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing

October 15, 2024

IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics

October 14, 2024

Featured Content

From Skepticism to Success: Insights Into Biosimilar Market Acceptance

October 13th 2024

By Cameron Santoro

Video

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the US, emphasizing partnerships for market growth.

Pharmacokinetic Modeling Proposes Cost-Effective Dosing for Adalimumab, Etanercept Biosimilars

October 12th 2024

By Deana Ferreri, PhD

Article

A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.

FDA Approves Imuldosa, a Biosimilar to Stelara

October 11th 2024

By Skylar Jeremias

Article

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share

October 11th 2024

By Skylar Jeremias

Article

Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.

The Top 5 Biosimilar Articles for the Week of October 7

October 11th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of October 7, 2024.

Sandoz Report: A Unified Approach to Overcoming Drug Shortages

October 10th 2024

By Skylar Jeremias

Article

A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.

Duke Publishes Recommendations for Developing CGT Biosimilars

October 9th 2024

By Skylar Jeremias

Article

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex biologics limit competition, requiring policies that support the development of biosimilars to enhance affordability and patient access.

Biosimilar Rituximab Safe, Effective for SLE After Switching

October 8th 2024

By Cameron Santoro

Article

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus erythematosus (SLE).

BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US

October 7th 2024

By Sarfaraz K. Niazi, PhD

Article

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.

Biosimilars Policy Roundup for September 2024—Podcast Edition

October 6th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.